These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37066770)

  • 21. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas.
    Klein CH; Truxius DC; Vogel HA; Harizanova J; Murarka S; Martín-Gago P; Bastiaens PIH
    Int J Cancer; 2019 Feb; 144(4):767-776. PubMed ID: 30194764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tubulin inhibitors: pharmacophore modeling, virtual screening and molecular docking.
    Niu MM; Qin JY; Tian CP; Yan XF; Dong FG; Cheng ZQ; Fida G; Yang M; Chen HY; Gu YQ
    Acta Pharmacol Sin; 2014 Jul; 35(7):967-79. PubMed ID: 24909516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of Novel Anoctamin1 (ANO1) Inhibitors Using 3D-QSAR Pharmacophore Modeling and Molecular Docking.
    Lee YH; Yi GS
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30336555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening for the selective inhibitors of MMP-9 from natural products based on pharmacophore modeling and molecular docking in combination with bioassay experiment, hybrid QM/MM calculation, and MD simulation.
    Hou J; Zou Q; Wang Y; Gao Q; Yao W; Yao Q; Zhang J
    J Biomol Struct Dyn; 2019 Aug; 37(12):3135-3149. PubMed ID: 30079817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacophore-based drug design for the identification of novel butyrylcholinesterase inhibitors against Alzheimer's disease.
    Jiang Y; Gao H
    Phytomedicine; 2019 Feb; 54():278-290. PubMed ID: 30668379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacophore modelling, docking and molecular dynamic simulation studies in the discovery of potential human renin inhibitors.
    Halimi M; Hajipasha A
    J Mol Graph Model; 2022 Nov; 116():108272. PubMed ID: 35932508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-based pharmacophore modeling for precision inhibition of mutant ESR2 in breast cancer: A systematic computational approach.
    Islam S; Amin MA; Rengasamy KRR; Mohiuddin AKM; Mahmud S
    Cancer Med; 2024 Aug; 13(15):e70074. PubMed ID: 39101505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of potential inhibitors for stat3: ligand based 3D pharmacophore, virtual screening, molecular docking, dynamic studies and
    Lakshmanan K; T K P; K Pai SR; Rajagopal K; Byran G
    J Biomol Struct Dyn; 2022; 40(21):11320-11338. PubMed ID: 34463213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacophore-Based Virtual Screening and In-Silico Explorations of Biomolecules (Curcumin Derivatives) of
    Ejaz SA; Aziz M; Fawzy Ramadan M; Fayyaz A; Bilal MS
    Molecules; 2023 May; 28(10):. PubMed ID: 37241785
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Vaghefinezhad N; Farsani SF; Gharaghani S
    Curr Drug Discov Technol; 2021; 18(1):139-157. PubMed ID: 31721705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
    Islam MA; Pillay TS
    J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DFT and molecular simulation validation of the binding activity of PDEδ inhibitors for repression of oncogenic k-Ras.
    Majrashi TA; Sabt A; Almahli H; El Hassab MA; Noamaan MA; Elkaeed EB; Hamissa MF; Maslamani AN; Shaldam MA; Eldehna WM
    PLoS One; 2024; 19(3):e0300035. PubMed ID: 38457483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigation of novel ligand targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery: complete pharmacophore approach.
    Shanmugam V; Muthukrishnan S
    J Biomol Struct Dyn; 2023; 41(23):14524-14539. PubMed ID: 36841551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular insight into isoform specific inhibition of PI3K-α and PKC-η with dietary agents through an ensemble pharmacophore and docking studies.
    Bhaskar BV; Rammohan A; Babu TM; Zheng GY; Chen W; Rajendra W; Zyryanov GV; Gu W
    Sci Rep; 2021 Jun; 11(1):12150. PubMed ID: 34108504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development, evaluation and application of 3D QSAR Pharmacophore model in the discovery of potential human renin inhibitors.
    John S; Thangapandian S; Arooj M; Hong JC; Kim KD; Lee KW
    BMC Bioinformatics; 2011 Dec; 12 Suppl 14(Suppl 14):S4. PubMed ID: 22372967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of potential inhibitors for HCV NS5b of genotype 4a by combining dynamic simulation, protein-ligand interaction fingerprint, 3D pharmacophore, docking and 3D QSAR.
    El-Hassab MAE; El-Bastawissy EE; El-Moselhy TF
    J Biomol Struct Dyn; 2020 Sep; 38(15):4521-4535. PubMed ID: 31647392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacophore-based virtual screening of ZINC database, molecular modeling and designing new derivatives as potential HDAC6 inhibitors.
    Poonia P; Sharma M; Jha P; Chopra M
    Mol Divers; 2023 Oct; 27(5):2053-2071. PubMed ID: 36214962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach.
    Zeb A; Park C; Son M; Rampogu S; Alam SI; Park SJ; Lee KW
    J Bioinform Comput Biol; 2018 Jun; 16(3):1840015. PubMed ID: 29945500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular dynamics simulation, 3D-pharmacophore and scaffold hopping analysis in the design of multi-target drugs to inhibit potential targets of COVID-19.
    Fayyazi N; Mostashari-Rad T; Ghasemi JB; Ardakani MM; Kobarfard F
    J Biomol Struct Dyn; 2022; 40(22):11787-11808. PubMed ID: 34405765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ligand based 3D-QSAR model, pharmacophore, molecular docking and ADME to identify potential fibroblast growth factor receptor 1 inhibitors.
    Huang L; Wu X; Fu X; Wang H; Tang B; Xiao Y; Zhou C; Zhao Z; Wan Y; Chen H; Tang Z; Yao H; Shan Z; Bu T
    J Biomol Struct Dyn; 2022 Oct; 40(16):7584-7597. PubMed ID: 33734039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.